Company / Revenue
Aquestive Therapeutics, Inc. Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$44.5M
FY2025
5-year range
$44.5M / $57.6M
FY2021-FY2025
Trend
-22.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 8 years, ranging from $45M in FY2025 to $67M in FY2019.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -3.3%.
Declined from $51M to $45M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -2.2%
- 5-Year CAGR
- -3.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.3%, indicating a declining trend.
- In FY2025, revenue decreased 22.6% year-over-year.
- Peak revenue was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.5M | -22.6% |
| FY2024 | $57.6M | +13.8% |
| FY2023 | $50.6M | +6.1% |
| FY2022 | $47.7M | +4.0% |
| FY2021 | $45.8M | -12.8% |
| FY2020 | $52.6M | -22.0% |
| FY2019 | $67.4M | +0.8% |
| FY2018 | $66.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026